BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu L, Feng J, Li J, Yu Q, Ji J, Wu J, Dai W, Guo C. The gut microbiome-bile acid axis in hepatocarcinogenesis. Biomed Pharmacother 2021;133:111036. [PMID: 33378947 DOI: 10.1016/j.biopha.2020.111036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ni Y, Lu M, Xu Y, Wang Q, Gu X, Li Y, Zhuang T, Xia C, Zhang T, Gou X, Zhou M. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease. Front Microbiol 2022;13:908011. [DOI: 10.3389/fmicb.2022.908011] [Reference Citation Analysis]
3 Liu C, Huang R, Yu H, Gong Y, Wu P, Feng Q, Li X. Fuzheng Xiaozheng prescription exerts anti-hepatocellular carcinoma effects by improving lipid and glucose metabolisms via regulating circRNA-miRNA-mRNA networks. Phytomedicine 2022;103:154226. [DOI: 10.1016/j.phymed.2022.154226] [Reference Citation Analysis]
4 Cheng W, Wang Y, Liu J, Li X, Yu M, Duan C, Liu L, Zhang J. Hepatotoxicity of cantharidin is associated with the altered bile acid metabolism. J Appl Toxicol 2021. [PMID: 34866203 DOI: 10.1002/jat.4267] [Reference Citation Analysis]
5 Yu Q, Dai W, Ji J, Wu L, Feng J, Li J, Zheng Y, Li Y, Cheng Z, Zhang J, Wu J, Xu X, Guo C. Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17322] [Reference Citation Analysis]
6 Li Y, Lee AQ, Lu Z, Sun Y, Lu JW, Ren Z, Zhang N, Liu D, Gong Z. Systematic Characterization of the Disruption of Intestine during Liver Tumor Progression in the xmrk Oncogene Transgenic Zebrafish Model. Cells 2022;11:1810. [PMID: 35681505 DOI: 10.3390/cells11111810] [Reference Citation Analysis]
7 Wen Tan SL, Israeli E, Ericksen RE, Chow PK, Han W. The altered lipidome of hepatocellular carcinoma. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Farhat Z, Freedman ND, Sampson JN, Falk RT, Koshiol J, Weinstein SJ, Albanes D, Sinha R, Loftfield E. A prospective investigation of serum bile acids with risk of liver cancer, fatal liver disease, and biliary tract cancer. Hepatol Commun 2022. [PMID: 35678016 DOI: 10.1002/hep4.2003] [Reference Citation Analysis]
9 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zhang Y, Zhang Y, Shi X, Li J, Wang L, Xie C, Wang Y. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Front Oncol 2022;12:836333. [DOI: 10.3389/fonc.2022.836333] [Reference Citation Analysis]
11 Hu S, Chen Y, Zhao S, Sun K, Luo L, Zeng L. Ripened Pu-Erh Tea Improved the Enterohepatic Circulation in a Circadian Rhythm Disorder Mice Model. J Agric Food Chem 2021;69:13533-45. [PMID: 34726418 DOI: 10.1021/acs.jafc.1c05338] [Reference Citation Analysis]
12 Chavez-tapia NC, Murúa-beltrán Gall S, Ordoñez-vázquez AL, Nuño-lambarri N, Vidal-cevallos P, Uribe M. Understanding the Role of Metabolic Syndrome as a Risk Factor for Hepatocellular Carcinoma. JHC 2022;Volume 9:583-93. [DOI: 10.2147/jhc.s283840] [Reference Citation Analysis]
13 Zhang N, Liu J, Guo X, Li S, Wang F, Wang M. Armillaria luteo-virens Sacc Ameliorates Dextran Sulfate Sodium Induced Colitis through Modulation of Gut Microbiota and Microbiota-Related Bile Acids. Nutrients 2021;13:3926. [PMID: 34836184 DOI: 10.3390/nu13113926] [Reference Citation Analysis]
14 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Liu Z, Li Y, Li C, Lei G, Zhou L, Chen X, Jia X, Lu Y. Intestinal Candida albicans Promotes Hepatocarcinogenesis by Up-Regulating NLRP6. Front Microbiol 2022;13:812771. [PMID: 35369462 DOI: 10.3389/fmicb.2022.812771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hu S, Luo L, Zeng L. Tea combats circadian rhythm disorder syndrome via the gut-liver-brain axis: potential mechanisms speculated. Crit Rev Food Sci Nutr 2022;:1-22. [PMID: 35187990 DOI: 10.1080/10408398.2022.2040945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Wu L, Li J, Feng J, Ji J, Yu Q, Li Y, Zheng Y, Dai W, Wu J, Guo C. Crosstalk between PPARs and gut microbiota in NAFLD. Biomed Pharmacother 2021;136:111255. [PMID: 33485064 DOI: 10.1016/j.biopha.2021.111255] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Usman M, Patil PJ, Mehmood A, Rehman A, Shah H, Haider J, Xu K, Zhang C, Li X. Comparative evaluation of pseudocereals peptides: A review of their nutritional contribution. Trends in Food Science & Technology 2022. [DOI: 10.1016/j.tifs.2022.02.009] [Reference Citation Analysis]
20 Vitale G, Mattiaccio A, Conti A, Turco L, Seri M, Piscaglia F, Morelli MC. Genetics in Familial Intrahepatic Cholestasis: Clinical Patterns and Development of Liver and Biliary Cancers: A Review of the Literature. Cancers 2022;14:3421. [DOI: 10.3390/cancers14143421] [Reference Citation Analysis]
21 Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, Yu-Lun K, Chou SH, Luo JC, Hou MC, Huang YH. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2022;10:e004779. [PMID: 35738801 DOI: 10.1136/jitc-2022-004779] [Reference Citation Analysis]